首页> 外文期刊>Current Cardiovascular Risk Reports >Novel Approaches for the Treatment of the Patient with Resistant Hypertension: Renal Nerve Ablation
【24h】

Novel Approaches for the Treatment of the Patient with Resistant Hypertension: Renal Nerve Ablation

机译:抵抗性高血压患者的新型治疗方法:肾神经消融术

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Sympathetic innervation of the kidneys plays a major role in the pathogenesis of hypertension through modulation of renin secretion, glomerular filtration rate and renal absorption of sodium. Targeted interventions for renal nerve ablation are being developed for treatment of drug-resistant hypertension in the USA and the rest of the world. Early studies with the use of radiofrequency-based renal denervation systems have shown encouraging results with significant reduction of blood pressure in patients inadequately controlled despite nearly maximal drug therapy regimens. Thus far, the renal denervation procedure has been associated with minimal side effects. Long-term efficacy and safety beyond 3 years needs to be determined for renal nerve ablation. This review focuses on the physiology of the renal sympathetic system, the rationale for renal nerve ablation and current evidence in support of the available therapeutic renal denervation systems.
机译:肾脏的交感神经通过调节肾素分泌,肾小球滤过率和肾脏对钠的吸收,在高血压的发病机理中起主要作用。在美国和世界其他地区,针对肾神经消融的靶向干预措施正在开发中,以治疗耐药性高血压。早期使用基于射频的肾脏去神经系统的研究显示出令人鼓舞的结果,尽管药物治疗方案几乎是最大的,但是如果控制不充分,患者的血压会显着降低。迄今为止,肾神经支配术与最小的副作用有关。肾神经消融需要确定3年以上的长期疗效和安全性。这篇综述着重于肾脏交感神经系统的生理学,肾神经消融的原理以及支持可用的治疗性肾脏去神经系统的最新证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号